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Background: Uveal melanoma is characterised by mutations in GNAQ and GNA11, resulting in Ras/Raf/MEK/ERK pathway
activation. Treatment with selumetinib (AZD6244, ARRY-142886), a MEK1/2 inhibitor, results in antitumour effects in uveal
melanoma pre-clinical models. A randomised phase II trial demonstrated improved progression-free survival (PFS) and
response rate (RR) with selumetinib monotherapy versus chemotherapy with temozolomide or dacarbazine in patients
with metastatic uveal melanoma. Pre-clinically, selumetinib in combination with alkylating agents enhanced antitumour
activity compared with chemotherapy alone. We hypothesise that selumetinib in combination with dacarbazine will result
in improved clinical outcomes in patients with metastatic uveal melanoma versus dacarbazine alone.
Methods/Design: SUMIT is a randomised, international, double-blind, placebo-controlled, phase III study assessing the
efficacy and safety of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma who
have not received prior systemic therapy. Primary endpoint is PFS. Secondary endpoints include objective RR, duration
of response, change in tumour size at Week 6, overall survival, safety and tolerability. Exploratory endpoints include
efficacy in tumours with GNAQ or GNA11 mutations. Eligible patients must have: ≥1 lesion that can be accurately
measured at baseline, and is suitable for accurate repeated measurements; ECOG performance status 0–1; life
expectancy >12 weeks. Mutation status for GNAQ/GNA11 will be assessed retrospectively.
An estimated 128 patients from approximately 50 sites globally will be randomised (3:1) to selumetinib 75 mg twice
daily or placebo in combination with dacarbazine 1000 mg/m2 on Day 1 of every 21-day cycle until objective disease
progression, intolerable toxicity or occurrence of another discontinuation criterion. Randomisation will be stratified by
the presence/absence of liver metastases. Tumours will be evaluated by RECIST v1.1 every 6 weeks. All patients have
the option of receiving selumetinib with or without dacarbazine at disease progression. Study enrolment began in
April 2014 and is expected to complete in early 2015.
Discussion: Treatment of patients with metastatic uveal melanoma represents an area of high unmet medical need.
This study evaluating selumetinib in combination with dacarbazine was designed with input from the US FDA, and is
the first potential registration trial to be conducted in patients with metastatic uveal melanoma.
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Trial registration: Clinicaltrials.gov (Date of registration, October 10, 2013)
Registration number: NCT01974752
Trial abbreviation: SUMIT
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Uveal melanoma is the most common primary tumour of
the eye [1]. Biologically distinct from cutaneous melan-
oma, it is a rare disease with an incidence per year of
about 1200–1500 new cases in the US, accounting for
around 5 % of all melanomas, and approximately 460
cases in Europe [2–4]. Metastasis is common, occurring
in approximately 50 % of patients with posterior uveal
melanoma within 15 years of the initial diagnosis and
treatment [5], and prognosis is poor with a median overall
survival (OS) of 4–15 months [6, 7].
Agents with regulatory approval for use in patients with
advanced cutaneous melanoma have only a limited role in
the treatment of advanced uveal melanoma, and there are
no approved or effective therapies for the treatment of pa-
tients with this disease [6]. Although immunotherapy with
ipilimumab has been demonstrated to improve survival in
patients with metastatic cutaneous melanoma [8] (NCCN
Practice Guidelines in Oncology melanoma version
4.2014 [http://www.nccn.org/professionals/physician_gls/
f_guidelines.asp#melanoma]), the efficacy of this agent in
uveal melanoma is not well defined. Analysis of single-
and multi-centre expanded access programmes indicates
modest radiographic response rates in patients with meta-
static uveal melanoma; however, any effect upon overall
survival has yet to be demonstrated [9–14]. Some benefit
has been observed with high dose interleukin-2, another
immunological agent to be approved for the treatment of
metastatic melanoma, in this patient population [15, 16].
Further prospective data are required to fully understand
the potential value of immunotherapy, including pembro-
lizumab which was recently approved in the US, in this
setting.
Vemurafenib and dabrafenib are small molecule in-
hibitors of BRAF approved for use in patients with ad-
vanced melanoma harbouring a V600 BRAF mutation
(NCCN Practice Guidelines in Oncology melanoma
version 4.2014 [www.nccn.org/professionals/physician_gls/
pdf/melanoma.pdf]). Antitumour efficacy is only observed
in cells harbouring a BRAF mutation, with paradoxical acti-
vation of the Ras/Raf/MEK/ERK pathway observed in cells
with wild-type BRAF [17–19]. Given that BRAF mutations
are absent or rare in uveal melanoma [20–22], there is no
utility for these agents in this disease.
Importantly, 80–96 % of uveal melanomas harbour
mutations in either the guanidine nucleotide bindingprotein (G protein), Q polypeptide 1 (GNAQ) or the G
protein alpha 11 (GNA11) gene, in a mutually exclusive
pattern [23–25]. Oncogenic mutations in GNAQ and
GNA11 result in constitutive activation of these pro-
teins and downstream signalling of pathways such as
the YAP pathway [26, 27], the phosphoinositide-3 kin-
ase/AKT [28] and the Ras/Raf/MEK/ERK pathway, thus
playing a key role in the development and progression
of uveal melanomas [23, 24, 29]. This biology suggests
that inhibition of one or more of these signalling path-
ways may result in antitumour activity.
Selumetinib (AZD6244; ARRY-142886) is an orally
available, potent and selective, non-ATP-competitive
mitogen-activated protein kinase (MEK1/2) inhibitor
[30]. In pre-clinical tumour models, selumetinib dem-
onstrates single agent anti-cancer activity [31], includ-
ing in models of uveal melanoma harbouring GNAQ or
GNA11 mutations [32, 33].
In a hypothesis-generating phase II open-label study,
patients with metastatic uveal melanoma, who were ei-
ther temozolomide or dacarbazine treatment naïve,
achieved an improved progression-free survival (PFS)
with selumetinib versus chemotherapy alone with tem-
ozolomide or dacarbazine (15.9 vs 7 weeks; hazard ratio
[HR] 0.46 [95 % confidence interval (CI) 0.30, 0.71];
p < 0.001). Tumour regression was observed in 49 % of
patients treated with selumetinib. No Response Evalu-
ation Criteria In Solid Tumors (RECIST) responses were
observed in patients treated with chemotherapy [34].
Pre-clinical work has identified several promising strat-
egies to improve the efficacy achieved with selumetinib
alone, including the concurrent administration of che-
motherapy with selumetinib, which results in increased
expression of pro-apoptotic proteins such as BIM [35].
When evaluated in combination with chemotherapy, selu-
metinib enhanced antitumour efficacy compared with
each agent alone, with particular sensitivity to BRAF/RAS-
mutant tumours [31]. Selumetinib in combination with
temozolomide, which has the same active metabolite as
dacarbazine, enhanced tumour growth inhibition, DNA
damage and apoptosis in a RAS-mutant tumour model
versus temozolomide monotherapy [35]. A series of clin-
ical trials assessing the efficacy of selumetinib in combin-
ation with chemotherapy have shown promise in patients
with mutations associated with the KRAS and BRAF path-
ways [36, 37], including in combination with dacarbazine
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unknown melanoma [37].
This pre-clinical [31, 35] and clinical evidence [34, 36, 37]
suggests that targeting the Ras/Raf/MEK/ERK pathway
in combination with chemotherapy is an attractive ther-
apy option to investigate in this disease setting. We there-
fore hypothesise that selumetinib in combination with
dacarbazine, an alkylating agent approved for use in the
treatment of advanced melanoma [38] (NCCN Practice
Guidelines in Oncology melanoma version 4.2014
[www.nccn.org/professionals/physician_gls/pdf/melanoma.
pdf]), may offer improved clinical outcomes in patients
with metastatic uveal melanoma versus dacarbazine alone.
Methods/Design
Study objectives
The primary objective is to assess the efficacy of selu-
metinib in combination with dacarbazine compared
with placebo in combination with dacarbazine in terms
of PFS in patients with metastatic uveal melanoma
(Table 1). Assessment will be by blinded independent
central review (BICR) of computed tomography (CT)
or magnetic resonance imaging (MRI) scans according
to RECIST v1.1.
Secondary objectives include further assessment of
efficacy in terms of OS and objective response rate
(ORR), duration of response (DoR), change in tumour
size at Week 6, safety and tolerability. Exploratory objec-
tives include assessment of mutations in GNAQ/GNA11,
health-related quality of life (HRQoL) and biomarkers
for response or development of cancer.
Trial design and treatment plan
SUMIT (NCT01974752) is a randomised, international,
double-blind, placebo-controlled phase III study asses-
sing the efficacy and safety of selumetinib (75 mg, twice
daily on a continuous oral administration) in combin-
ation with dacarbazine (1000 mg/m2, intravenously on
Day 1 of every 21-day cycle) compared with matched
placebo in combination with dacarbazine (same schedule)Table 1 Key study objectives
Primary objective Exploratory obje
• Progression-free survival • Overall surviva
Secondary objectives • Symptoms and
• Objective response rate • Hospital-related
• Duration of response • Pharmacokinet
• Change in tumour size at Week 6 • Explore MEK p
• Overall survival • Biomarkers for
• Safety and tolerability profile • Host genetic p
AE adverse event, EORTC-QLQC30 v3 European Organisation for Research and Treatm
GNAQ guanidine nucleotide binding protein (G protein), Q polypeptide 1, GNA11 Gin patients who have not previously had a systemic ther-
apy for metastatic uveal melanoma (Fig. 1).
Patients will be randomised in a 3:1 ratio to receive selu-
metinib in combination with dacarbazine or placebo in
combination with dacarbazine, and stratified by the pres-
ence/ absence of liver metastases (yes/no) at randomisation.
Following confirmation of objective disease progression by
BICR, all patients have the option of receiving open-label
selumetinib with or without dacarbazine or an alternative
treatment approach.
All randomised patients will be assessed by CT or MRI
at screening, Week 6 and every 6 weeks thereafter, relative
to the date of randomisation until objective disease pro-
gression regardless of whether or not they are on study
treatment. Up to the data cut-off for the primary analysis,
RECIST v1.1, defined by BICR, will be used to assess each
patient’s tumour response to treatment and allow calcula-
tions of PFS, ORR, duration of response and tumour size
at Week 6. For patients receiving open-label selumetinib
with or without dacarbazine, tumour assessments will be
performed in accordance with local practice at the investi-
gational site and will not be sent for BICR.
Adverse events (AEs) will be collected from the time
of informed consent, coded using the Medical Dictionary
for Regulatory Activities (MedDRA), and graded using
the National Cancer Institute Common Terminology
Criteria for Adverse Events (CTCAE). AEs will continue
to be collected for patients who opt to receive open-
label selumetinib (either alone or in combination with
dacarbazine) as post-progression therapy.
Ophthalmologic examinations and echocardiogram/
multi-gated acquisitions will be performed at rando-
misation and then every 6 and 12 weeks, respectively,
thereafter or as clinically indicated. For both, a 30-day
follow-up assessment will be required if an on-treatment
assessment was abnormal at the time of discontinuation
of selumetinib/placebo, to confirm reversibility of the
abnormality.
The European Organization for Research and Treat-
ment of Cancer 30-item core quality of life questionnairectives
l adjusting for the impact of treatment options available post-progression
HRQoL using the EORTC-QLQC30 v3
resource use and health state utility
ics versus clinical outcomes, efficacy, AEs and/or safety parameters
athway mutations in GNAQ and GNA11
response or development of cancer
olymorphisms
ent of Cancer 30-item core quality of life questionnaire version 3,
























3 weeks until 
discontinuation or 
disease progression
Patients with metastatic uveal melanoma, 
with no prior systemic therapy
Randomisation (3:1 ratio) stratified by the 
presence/absence of liver metastases (Day 1)
Selumetinib 75 mg 




administered iv on Day 1 
of every 21-day cycle




administered iv on Day 1 
of every 21-day cycle
Administered until objective 
disease progression, 
intolerable toxicity or 
occurrence of another 
discontinuation criterion
Fig. 1 Study design. iv = intravenous
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thereafter every 3 weeks following randomisation until
objective disease progression or death.
Archival tumour samples will be collected for all ran-
domised patients for the assessment of GNAQ/GNA11
mutation status. In addition, patients will provide plasma
samples for analysis of circulating free tumour DNA.
Correlation between tumour and plasma-based mutation
analysis will be assessed.
All patients are required to provide written informed
consent. The study will be performed in accordance with
the Declaration of Helsinki and the International Con-
ference on Harmonisation Good Clinical Practice. The
protocol was approved by the Institutional Review Board
at each study site (approximately 50 sites, Table 2) and
complied with local country regulations.Study population
Patients will be eligible for inclusion if they are ≥18 years of
age with a clinical diagnosis of metastatic uveal melanoma
(histologically or cytologically confirmed), and have ≥1
lesion that can be accurately measured at baseline, and is
suitable for accurate repeated measurements. Patients must
have an Eastern Cooperative Oncology Group (ECOG) per-
formance status 0–1, a life expectancy >12 weeks and be
able to provide informed consent.
Patients will be excluded from the study if they have
received previous treatment with a systemic anticancer
therapy, or have symptomatic brain metastases or spinal
cord compression. Full patient selection criteria are pre-
sented in Table 3.Statistical methods
An estimated 128 patients with metastatic uveal melan-
oma will be randomised 3:1 to the selumetinib plus
dacarbazine group (96 patients) or placebo plus dacarba-
zine group (32 patients), to obtain approximately 93 PFS
events. The sample size is driven by the number of re-
quired events. Assuming a true PFS HR of 0.46 [34], this
number of events will provide 90 % power to demon-
strate a statistically significant difference for PFS at a
5 % 2-sided significance level. OS will be analysed at the
time of PFS analysis and updated at 65 % maturity
(approximately 83 events). Assuming a true OS HR of
0.49, with 83 deaths, the trial has 80 % power to demon-
strate a statistically significant difference for OS with a
1-sided type-1 error of 2.43 %. The type-1 error has been
adjusted to allow for a single interim analysis based on
approximately 45 death events.
Efficacy analyses will be performed on the efficacy ana-
lysis set on an intent-to-treat (ITT) basis according to ran-
domised treatment. PFS, based on BICR, and OS will be
analysed by a stratified log-rank test, with the presence of
liver metastases at randomisation included as a stratifica-
tion factor. The effect of treatment will be estimated by
the HR together with its corresponding 2-sided CI and
p-value. Kaplan-Meier plots of PFS and OS will also be
presented. ORR (based on BICR) will be analysed using a
logistic regression adjusted for the stratification factor
presence/absence of liver metastases.
To describe the nature of benefits of selumetinib treat-
ment, PFS, ORR and OS will be tested at a 2-sided
significance level of 5 (PFS and ORR based on BICR).
In order to strongly control the type-1 error at 2.5 %
Table 2 Ethics committees
Research site Ethics committee
USA
Los Angeles, CA University of California Los Angeles, Institutional
Review Board
Aurora, CO Western Institutional Review Board
Miami Beach, FL Mount Sinai Medical Center, Institutional Review
Board
Atlanta, GA Emory University, Institutional Review Board
Lutherville, MD John Hopkins Medicine, Office of Human Subjects
Research, Institutional Review Board
Rochester, MN Mayo Clinic, Institutional Review Board
St Louis, MO Washington University in St Louis, Human Research
Protection Office
Morristown, NJ Atlantic Health System, Institutional Review Board
New York, NY Columbia University Medical Center, Institutional
Review Board
New York, NY Memorial Sloan-Kettering Cancer Center,
Institutional Review Board
Chapel Hill, NC The University of North Carolina at Chapel Hill,
Office of Human Research Ethics
Philadelphia, PA Jefferson, Office of Human Research Ethics,
Institutional Review Board
Charleston, SC Western Institutional Review Board
Charlottesville, VA University of Virginia, Institutional Review Board
Belgium
Edegem Ethisch Comite Unversitair Ziekenhuis Antwerpen
Gent Ethisch Comite Unversitair Ziekenhuis Antwerpen
Kortrijk Ethisch Comite Unversitair Ziekenhuis Antwerpen
Leuven Ethisch Comite Unversitair Ziekenhuis Antwerpen
Canada
Toronto, ON University Health Network Research Ethics Board
Montreal, QC Comité d’éthique de la recherche du CHUM
Czech Republic
Hradec Kralove Eticka komise Fakultni nemocnice Hradec Kralove
Olomouc Eticka komise Fakultni nemocnice Olomouc a
Lekarske UP v Olomouci
Prague Eticka komise Pri Institutu Klinicke a experimentalni
Mediciny a Thomayerove Nemocnici
Finland
Hus Varsinais-Suomen sairaanhoitopiirin kuntayhtyma
Tampere Varsinais-Suomen sairaanhoitopiirin kuntayhtyma
France
Nice Groupe Hospitalier Pitie-Salpetriere
Paris Groupe Hospitalier Pitie-Salpetriere
Germany
Heidelberg Ethikkommission Bei Der LMU Munchen
Munich Ethikkommission Bei Der LMU Munchen
Table 2 Ethics committees (Continued)
Israel
Jerusalem Ethics Helsinki Committee at Hadassah University
Hospital
Ramat Gan Helsinki Committee Clinical Trials Approval
Committee Tel Hashomer Medical Center
Netherlands
Leiden Commissie Medische Ethiek H1-Q
Spain
Barcelona Hospital Universitario ramon y cajal Clinical Research
Ethics Committee




Hospital Universitario Ramon y Cajal Clinical Research
Ethics Committee
Madrid Hospital Universitario Ramon y Cajal Clinical Research
Ethics Committee
Madrid Hospital Universitario Ramon y Cajal Clinical Research
Ethics Committee
Seville Hospital Universitario Ramon y Cajal Clinical Research
Ethics Committee
Valencia Hospital Universitario Ramon y Cajal Clinical Research
Ethics Committee
UK
Birmingham NRES Committee London
Glasgow NRES Committee London
Northwood NRES Committee London
Nottingham NRES Committee London
Southampton NRES Committee London
Swansea NRES Committee London
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exhaustive recycling strategy [39] will also be employed
across the primary endpoint PFS and secondary endpoints
ORR and OS. No formal statistical testing will be per-
formed on the safety data. AEs will be summarised by pre-
ferred term and system organ class (using MedDRA).
Summaries of AEs by causality and National Cancer Insti-
tute CTCAE grade will also be presented.
Data for exploratory patient-reported outcome end-
points will be analysed descriptively for the efficacy (ITT)
analysis set. Data will be presented in terms of minimum,
maximum, mean, standard deviation and median scores
together with 95 % CIs at each visit as well as change
from baseline to each scheduled visit (including end of
treatment).
Discussion
We hypothesise that selumetinib in combination with
dacarbazine will provide improved clinical outcomes ver-
sus dacarbazine alone in patients with metastatic uveal
melanoma. This is founded on the encouraging results
Table 3 Key patient selection criteria
Inclusion criteria Exclusion criteria
• Clinical diagnosis of metastatic uveal melanoma • Any prior systemic anticancer therapy, including for the treatment of
this current diagnosis
• Histological or cytological confirmation of melanoma • An investigational drug within 30 days of starting treatment, or has
not recovered from side effects of an investigational drug
• Male or female aged ≥18 years
• Suitable for treatment with dacarbazine chemotherapy • Any non-systemic anticancer therapy that has not been cleared from
the body by the time of starting study treatment
• ≥1 lesion that can be accurately measured at baseline as ≥10 mm in the
longest diameter, which is suitable for accurate repeated measurements • Radiation therapy within 4 weeks prior to starting study treatment
• Major surgery within 4 weeks prior to entry into the study that would
prevent administration of study treatment
• ECOG performance status 0–1
• Life expectancy >12 weeks
• Normal organ and marrow function • Any prior investigational therapy comprising inhibitors of RAS, RAF or
MEK at any time
• Negative urinary or serum pregnancy test for women with childbearing
potential • Previous treatment with dacarbazine
• Able to swallow selumetinib/placebo capsules • Any unresolved toxicity > CTCAE grade 2 from previous anticancer
therapy, excluding alopecia
• Signed informed consent document
• History of allergic reactions attributed to compounds of similar
chemical or biologic composition to selumetinib or dacarbazine
• Symptomatic brain metastases or spinal cord compression
• Cardiac conditions, such as uncontrolled hypertension, acute coronary
syndrome, uncontrolled angina or heart failure
• Severe concomitant systemic disorder, active infection, active bleeding
diatheses or renal transplant
• Refractory nausea and vomiting, chronic gastrointestinal diseases or
significant bowel resection that would preclude adequate absorption
• History of another primary malignancy within 5 years prior to starting
study treatment
• Current or past history of retinal pigmented epithelial detachment/
central serous retinopathy; retinal vein occlusion; intraocular pressure
>21 mmHg; uncontrolled glaucoma
• Female patients who are breast-feeding and male or female patients of
reproductive potential who are not employing an effective method of
birth control
• Judgement by the investigator that the patient should not participate
in the study
CTCAE Common Terminology Criteria for Adverse Events, ECOG Eastern Cooperative Oncology Group
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significant improvement in PFS for patients with meta-
static uveal melanoma receiving selumetinib compared
with those receiving chemotherapy (HR 0.46; 95 % CI
0.30, 0.71; p < 0.001) [34]. A comparable PFS improve-
ment to that in the overall population was observed in
patients with tumours harbouring a mutation in GNAQ
or GNA11 [34].
This phase III trial will build on pre-clinical and clinical
evidence assessing the efficacy of selumetinib in combin-
ation with chemotherapy. Pre-clinically, the combination
of selumetinib with chemotherapy has been shown to in-
crease the cytotoxicity of chemotherapy alone [31], includ-
ing in RAS-mutant tumour models, i.e. cells dependent on
the Ras/Raf/MEK/ERK pathway [35]. Clinically, two phase
II trials have demonstrated the efficacy of selumetinib incombination with chemotherapy in patients with Ras/Raf/
MEK/ERK-pathway-dependent cancer [36, 37]. As noted,
tumours dependent on the Ras/Raf/MEK/ERK pathway
include uveal melanomas harbouring oncogenic GNAQ/
GNA11 mutations [24]. Thus, the combination of selume-
tinib with chemotherapy in this disease setting may pose a
favourable treatment approach.
Dacarbazine was selected as the therapy for use in
combination with selumetinib in this study based on
a number of factors. Selumetinib in combination with
temozolomide (which has the same active metabolite
as dacarbazine but does not require liver metabolism
for activation [40]) enhanced the antitumour effect of
temozolomide monotherapy [35]. Although this study
utilised a human colorectal tumour xenograft model, it
provides positive evidence for the efficacy of selumetinib
Carvajal et al. BMC Cancer  (2015) 15:467 Page 7 of 9in combination with temozolomide/dacarbazine in a
RAS-mutant model. The combination of selumetinib and
dacarbazine has demonstrated clinical activity in a phase
II trial, with significant improvements in PFS observed in
patients with BRAF mutation-positive advanced cutane-
ous or unknown melanoma receiving the combination
versus dacarbazine alone [37]. Clinically, dacarbazine is
the only chemotherapy approved for use in the treatment
of melanoma (NCCN Practice Guidelines in Oncology
melanoma version 4.2014 [www.nccn.org/professionals/
physician_gls/pdf/melanoma.pdf]) and is the most com-
monly prescribed chemotherapy for both metastatic cuta-
neous and uveal melanoma. Taken together, these data
provide the rationale for selecting dacarbazine as the
combination agent for selumetinib in this study.
To address concerns that dacarbazine may be a less
optimal therapy than selumetinib for patients with uveal
melanoma, based on the encouraging clinical efficacy with
selumetinib in this patient population [34], an unequal
randomisation ratio (3:1) will be used in this study for
selumetinib and dacarbazine. The evaluation of response
at Week 6 and every 6 weeks thereafter will enable the
identification of early progressors on chemotherapy and
permit rapid crossover of patients to selumetinib, if
required. At the point of objective disease progression,
patients will have the option of receiving open-label selu-
metinib with or without dacarbazine. In the phase II study,
86 % of patients with metastatic uveal melanoma were
clinically sufficiently fit to receive selumetinib treatment
after experiencing disease progression with temozolomide
or dacarbazine. In these patients, efficacy with selumetinib
was lower with a median PFS of 8 weeks (95 % CI 8,
12 weeks) compared with 15.9 weeks (95 % CI 8.4,
21.1 weeks) when selumetinib was given initially [34].
However, these findings need to be interpreted with
caution as this was a post-hoc analysis, and the reasons
behind these findings are not clear.
As the treatment of patients with metastatic uveal
melanoma represents an area of high unmet medical
need, the results of the described phase II studies,
coupled with pre-clinical and clinical evidence, provide
the rationale for assessing selumetinib in combination
with dacarbazine in this patient population. This study is
the first potential registration trial to be conducted in
patients with metastatic uveal melanoma and was de-
signed with input from the US Food and Drug Adminis-
tration (FDA). Study enrolment began in April 2014 and
the study is expected to complete in early 2015.
Abbreviations
AE: Adverse event; BICR: Blinded independent central review; BID: Twice
daily; CI: Confidence interval; CT: Computed tomography; CTCAE: Common
Terminology Criteria for Adverse Events; DoR: Duration of response;
ECOG: Eastern Cooperative Oncology Group; EORTC-QLQC30 v3: European
Organisation for Research and Treatment of Cancer 30-item core quality of
life questionnaire version 3; FDA: Food and Drug Administration; Gprotein: Guanidine nucleotide binding protein; GNA11: Guanidine nucleotide
binding protein alpha 11; GNAQ: Guanidine nucleotide binding protein, Q
polypeptide 1; HR: Hazard ratio; HRQoL: Health-related quality of life;
ITT: Intent-to-treat; iv: Intravenous; MedDRA: Medical Dictionary for
Regulatory Activities; MEK: Mitogen-activated protein kinase; MRI: Magnetic
resonance imaging; ORR: Objective response rate; OS: Overall survival;
PFS: Progression-free survival; RECIST: Response Evaluation Criteria In Solid
Tumors.
Competing interests
RC is a consultant for AstraZeneca. GS has received honoraria from
AstraZeneca and served on its recent advisory board for the selumetinib
drug programme. PN received fees from AstraZeneca for an advisory board.
HM is an employee of AstraZeneca and IS is a former employee of
AstraZeneca.
Authors’ contributions
RC, GS, PN and IS participated in the design of the study. HM designed the
statistical analysis plan. All authors contributed to the implementation of the
study, were involved in revising the manuscript critically, and gave their final
approval of the version to be published.
Authors’ information
Ian Smith is no longer an AstraZeneca employee.
Acknowledgements
The study is funded by AstraZeneca. Medical writing services were provided
by Sandra Brave of iMed Comms and were funded by AstraZeneca. The
authors thank in advance all of the patients, investigators and institutions
that will be involved in this study.
Author details
1Division of Hematology/Oncology, Columbia University Medical Center,
New York, NY 10032, USA. 2AstraZeneca, Macclesfield, UK. 3Mt Vernon Cancer
Centre, Northwood, UK.
Received: 9 January 2015 Accepted: 26 May 2015
References
1. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on
cutaneous and noncutaneous melanoma: a summary of 84,836 cases from
the past decade. The American College of Surgeons Commission on Cancer
and the American Cancer Society. Cancer. 1998;83:1664–78.
2. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic
aspects of uveal melanoma. Surv Ophthalmol. 1988;32:239–51.
3. Ramaiya KJ, Harbour JW. Current management of uveal melanoma. Exp Rev
Ophthalmol. 2007;2:939–46.
4. Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, Lutz JM,
Paci E. Incidence of uveal melanoma in Europe. Ophthalmology.
2007;114:2309–15.
5. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with
malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:4651–9.
6. Augsburger JJ, Correa ZM, Shaikh AH. Effectiveness of treatments for
metastatic uveal melanoma. Am J Ophthalmol. 2009;148:119–27.
7. Postow MA, Kuk D, Bogatch K, Carvajal RD: Assessment of overall survival
from time of metastasis in mucosal, uveal, and cutaneous melanoma
[abstract]. J Clin Oncol 2014, 15(Suppl):Abstract 9074.
8. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB,
Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den
Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D,
Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS,
Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with
ipilimumab in patients with metastatic melanoma. N Engl J Med.
2010;363:711–23.
9. Alexander M, Mellor JD, McArthur G, Kee D. Ipilimumab in pretreated
patients with unresectable or metastatic cutaneous, uveal and mucosal
melanoma. Med J Aust. 2014;201:49–53.
10. Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R,
Boitano M, Calabro L, Rossi CD, Giacomo AM, Ferrucci PF, Ridolfi L,
Altomonte M, Miracco C, Balestrazzi A, Maio M. Ipilimumab in pretreated
Carvajal et al. BMC Cancer  (2015) 15:467 Page 8 of 9patients with metastatic uveal melanoma: safety and clinical efficacy.
Cancer Immunol Immunother. 2012;61:41–8.
11. Kelderman S, van der Kooij MK, van den Eertwegh AJ, Soetekouw PM,
Jansen RL, van den Brom RR, Hospers GA, Haanen JB, Kapiteijn E, Blank CU.
Ipilimumab in pretreated metastastic uveal melanoma patients. Results of
the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta
Oncol. 2013;52:1786–8.
12. Khattak MA, Fisher R, Hughes P, Gore M, Larkin J. Ipilimumab activity in
advanced uveal melanoma. Melanoma Res. 2013;23:79–81.
13. Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-
Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding
JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS,
Carvajal RD. Clinical activity of ipilimumab for metastatic uveal melanoma: a
retrospective review of the Dana-Farber Cancer Institute, Massachusetts
General Hospital, Memorial Sloan-Kettering Cancer Center, and University
Hospital of Lausanne experience. Cancer. 2013;119:3687–95.
14. Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi R, De Rosa
F, Del Vecchio M, Di Guardo L, Queirolo P, Picasso V, Marchetti P, De Galitiis
F, Mandala M, Guida M, Simeone E, Ascierto PA. Efficacy and safety of
ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol.
2013;24:2911–5.
15. Becker JC, Terheyden P, Kampgen E, Wagner S, Neumann C, Schadendorf D,
Steinmann A, Wittenberg G, Lieb W, Brocker EB. Treatment of disseminated
ocular melanoma with sequential fotemustine, interferon alpha, and
interleukin 2. Br J Cancer. 2002;87:840–5.
16. Soni S, Lee DS, DiVito Jr J, Bui AH, DeRaffele G, Radel E, Kaufman HL.
Treatment of pediatric ocular melanoma with high-dose interleukin-2
and thalidomide. J Pediatr Hematol Oncol. 2002;24:488–91.
17. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R,
Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S,
Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS,
Malek S. RAF inhibitors prime wild-type RAF to activate the MAPK pathway
and enhance growth. Nature. 2010;464:431–5.
18. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N,
Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R. Kinase-dead BRAF
and oncogenic RAS cooperate to drive tumor progression through CRAF.
Cell. 2010;140:209–21.
19. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors
transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Nature. 2010;464:427–30.
20. Malaponte G, Libra M, Gangemi P, Bevelacqua V, Mangano K, D'Amico F,
Mazzarino MC, Stivala F, McCubrey JA, Travali S. Detection of BRAF gene
mutation in primary choroidal melanoma tissue. Cancer Biol Ther.
2006;5:225–7.
21. Cruz III F, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, Bainbridge T,
Heinrich MC, Corless CL. Absence of BRAF and NRAS mutations in uveal
melanoma. Cancer Res. 2003;63:5761–6.
22. Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R, Packer L, Borgstein
AM, Pavey S, van der Velden P, Out C, Jager MJ, Hayward NK, Gruis NA.
Activation of the MAPK pathway is a common event in uveal melanomas
although it rarely occurs through mutation of BRAF or RAS. Br J Cancer.
2005;92:2032–8.
23. Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM,
Harbour JW. Oncogenic mutations in GNAQ occur early in uveal melanoma.
Invest Ophthalmol Vis Sci. 2008;49:5230–4.
24. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S,
Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, Sozen MM,
Baimukanova G, Roy R, Heguy A, Dolgalev I, Khanin R, Busam K, Speicher
MR, O'Brien J, Bastian BC. Mutations in GNA11 in uveal melanoma. N Engl J
Med. 2010;363:2191–9.
25. Piperno-Neumann S, Kapiteijn E, Larkin JMG, Carvajal RD, Luke JJ, Seifert H,
Roozen I, Zoubir M, Ramkumar T, Emery C, Derti A, Yerramilli-Rao P, Hodi FS,
Schwartz GK: Landscape of genetic alterations in patients with metastatic
uveal melanoma [abstract]. J Clin Oncol 2014, 32(Suppl 5):Abstract 9043.
26. Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues
M, Zaidi MR, Ksander BR, Merlino G, Sodhi A, Chen Q, Gutkind JS. Hippo-
independent activation of YAP by the GNAQ uveal melanoma oncogene
through a trio-regulated Rho GTPase signaling circuitry. Cancer Cell.
2014;25:831–45.
27. Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng Z, Zhao L, Peyman G, Ouyang H,
Jiang W, Zhao J, Chen X, Zhang L, Wang CY, Bastian BC, Zhang K, Guan KL.Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.
Cancer Cell. 2014;25:822–30.
28. Ambrosini G, Musi E, Ho AL, de Stanchina E, Schwartz GK. Inhibition of
mutant GNAQ signaling in uveal melanoma induces AMPK-dependent
autophagic cell death. Mol Cancer Ther. 2013;12:768–76.
29. Bauer J, Kilic E, Vaarwater J, Bastian BC, Garbe C, de Klein A. Oncogenic
GNAQ mutations are not correlated with disease-free survival in uveal
melanoma. Br J Cancer. 2009;101:813–5.
30. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D,
Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD,
Koch K, Wallace E. Biological characterization of ARRY-142886 (AZD6244),
a potent, highly selective mitogen-activated protein kinase kinase 1/2
inhibitor. Clin Cancer Res. 2007;13:1576–83.
31. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M,
Cartlidge S, Smith PD. AZD6244 (ARRY-142886), a potent inhibitor of
mitogen-activated protein kinase/extracellular signal-regulated kinase
kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/
pharmacodynamic relationship, and potential for combination in preclinical
models. Mol Cancer Ther. 2007;6:2209–19.
32. Ambrosini G, Pratilas CA, Qin LX, Tadi M, Surriga O, Carvajal RD, Schwartz
GK. Identification of unique MEK-dependent genes in GNAQ mutant uveal
melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
Clin Cancer Res. 2012;18:3552–61.
33. Mitsiades N, Chew SA, He B, Riechardt AI, Karadedou T, Kotoula V, Poulaki V.
Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition
of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Invest
Ophthalmol Vis Sci. 2011;52:7248–55.
34. Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar
RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini
MR, Sato T, Lewis K, Doyle A, Ancell K, Panageas KS, Bluth M, Hedvat C,
Erinjieri J, Ambrosini G, Marr B, Abramson DH, Dickson MA, Wolchok JD,
Chapman PB, Schwartz GK. Effect of selumetinib vs chemotherapy on
progression-free survival in uveal melanoma: a randomized clinical trial.
JAMA. 2014;311:2397–405.
35. Holt SV, Logie A, Odedra R, Heier A, Heaton SP, Alferez D, Davies BR,
Wilkinson RW, Smith PD. The MEK1/2 inhibitor, selumetinib (AZD6244;
ARRY-142886), enhances anti-tumour efficacy when combined with
conventional chemotherapeutic agents in human tumour xenograft models.
Br J Cancer. 2012;106:858–66.
36. Janne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C,
Franke FA, Grinsted L, Zazulina V, Smith P, Smith I, Crino L. Selumetinib
plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer:
a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol.
2013;14:38–47.
37. Robert C, Dummer R, Gutzmer R, Lorigan P, Kim KB, Nyakas M, Arance A,
Liszkay G, Schadendorf D, Cantarini M, Spencer S, Middleton MR.
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line
treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind
randomised study. Lancet Oncol. 2013;14:733–40.
38. Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G:
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol 2012, 23(Suppl 7):vii86-vii91.
39. Burman CF, Sonesson C, Guilbaud O. A recycling framework for the
construction of Bonferroni-based multiple tests. Stat Med. 2009;28:739–61.
40. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant
glioma. Clin Cancer Res. 2000;6:2585–97.
Carvajal et al. BMC Cancer  (2015) 15:467 Page 9 of 9
